About this visual
A visual readout of tirzepatide plus ixekizumab in psoriatic arthritis and obesity.
Sources & further reading
Original LinkedIn post and discussion ↗
Additional references appear in the infographic and the original LinkedIn discussion.




Yesterday’s data from Eli Lilly regarding Zepbound suggests a new direction in how we approach the dual burden of Psoriatic Arthritis (PsA) and obesity.
The Phase 3b TOGETHER-PsA trial is the first controlled study to show that adding an incretin therapy to a biologic like Taltz does not just manage weight. It significantly improves the arthritis treatment response.
As highlighted in my infographic, the results are strong.
- The Primary Endpoint (Double Win): Nearly 32% of patients on combination therapy achieved both ACR50 clearance and greater than 10% weight loss at 36 weeks, compared to less than 1% on monotherapy.
- Improved Joint Response: Even when looking strictly at arthritis scores, adding tirzepatide resulted in a 64% relative increase in patients responding to the biologic.
For our patients living with both chronic inflammatory disease and adiposity, this data suggests that managing metabolic health acts as a disease-modifying factor for their arthritis.